The abstract is read at the publisher; the summary is JClub's.
Pretreatment immune suppression in early-stage bladder cancer predicts Bacillus Calmette-Guérin response, and BCG failure is linked to an MFAP2+ cancer-associated fibroblast–driven immunosuppressive microenvironment.
- Why it matters: More than half of early-stage bladder cancer patients fail BCG and later recur, and the role of tumor microenvironment heterogeneity in response is not well defined.
- What they did: The study assessed BCG response relative to tumor-infiltrating T-cell numbers and profiled the pretreatment microenvironment, identifying MFAP2+ CAF and testing how they affect BCG-induced antitumor immunity via interactions with T cells and tertiary lymphoid structures.
- The result: BCG response was not correlated with T-cell counts but was determined by the immunosuppressive microenvironment; cross-sectional data suggest stepwise immune evasion factor activation from MFAP2+ CAF to PD-L1 and then LAG3 on T cells, enabling potential prediction of BCG response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.